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Abstract
The BOADICEA breast cancer (BC) risk assessment model and its associatedWeb Application v3 (BWA) tool are being extended
to incorporate additional genetic and non-genetic BC risk factors. From an online survey through the BOADICEAwebsite and UK,
Dutch, French and Swedish national genetic societies, we explored the relationships between the usage frequencies of the BWA and
six other common BC risk assessment tools and respondents’ perceived importance of BC risk factors. Respondents (N = 443)
varied in age, country and clinical seniority but comprised mainly genetics health professionals (82%) and BWA users (93%).
Oncology professionals perceived reproductive, hormonal (exogenous) and lifestyle BC risk factors as more important in BC risk
assessment compared to genetics professionals (p values < 0.05 to 0.0001). BWAwas used more frequently by respondents who
gave high weight to breast tumour pathology and low weight to personal BC history as BC risk factors. BWA use was positively
related to the weight given to hormonal BC risk factors. The importance attributed to lifestyle and BMI BC risk factors was not
associated with the use of BWA or any of the other tools. Next version of the BWA encompassing additional BC risk factors will
facilitate more comprehensive BC risk assessment in genetics and oncology practice.
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Introduction
Breast cancer (BC) is a major public health problem for women
with almost 1.7 million new BC diagnoses and 521, 900 BC
deaths estimated worldwide in 2012 (DeSantis et al. 2015).
A number of BC risk factors have been identified, including
family history, breast density on mammogram, hormonal expo-
sure, reproductive history and lifestyle. A family history of BC
suggests the presence of an inherited genetic variant such as
those in the BRCA1 and BRCA2 genes which confer a Bhigh^
BC susceptibility (Couch et al. 2014). Recently, additional BC
genetic risk factors have been identified, including rare variants
in genes such as PALB2, CHEK2, ATM (Lee et al. 2016) asso-
ciated with Bmoderate^ to Bhigh^ risk and common Blow-risk^
variants (Kurian et al. 2016). Non-genetic BC risk factors in-
clude hormonal BC risk factors (e.g. use of hormone-
replacement therapy, oral contraception), reproductive BC risk
factors (e.g. age of first pregnancy, breastfeeding, age at menar-
che, age at menopause) and lifestyle BC risk factors (e.g. obe-
sity, physical activity, alcohol consumption) (Harvie et al. 2015).
Several models and tools have been developed to enable
healthcare professionals to assess the probability of developing
BC and/or of carrying a deleterious mutation. These models
account for the individual or combined effects of different BC
risk factors (Antoniou et al. 2008; Amir et al. 2010;Meads et al.
2012; Quante et al. 2012; Kurian et al. 2016; Cintolo-Gonzalez
et al. 2017). They can be used in clinical practice to appraise
needs for referral for genetic counselling and testing and to
inform decisions on riskmanagement options such as enhanced
screening, risk-reducing surgical interventions or chemopre-
vention (Padamsee et al. 2017). These models differ according
to the specific BC risk factors they incorporate, their develop-
mental method and clinical applications.
We report the results of a survey performed as part of the
BRIDGES research program (http://cordis.europa.eu/project/
rcn/193315_en.html) that aims to inform the development and
implementation of a comprehensive genetic test in BC risk
assessment and to combine this with additional non-genetic
BC risk factors. The latter will be achieved through further
development of the Breast and Ovarian Analysis of Disease
Incidence and Carrier Estimation Algorithm (BOADICEA)
model and BOADICEAWeb Application (BWA) (Lee et al.
2014, 2016).
Many BC risk assessment tools are currently available.
However, it is unclear which clinicians use them, why they
use them and whether these tools fulfil their requirements. In
particular, we wished to assess the clinical acceptability of the
BOADICEA model and the BWA. In a previous article
(Bredart et al. 2018), we reported on clinicians’ perceptions
of the BOADICEA model and BWA v3 tool in terms of us-
ability (e.g., data entry timing, risk communication format). In
this study, we explored the relationship between the perceived
importance attributed to BC risk factors by professional
profile, in relation to respondents’ knowledge and usage fre-
quencies of the BWA as well as of six other BC risk assess-
ment tools commonly used in family cancer clinics. The re-
sults of our analyses will help to identify perceived deficien-
cies in the BWA and guide further software development, so
that the next version of the tool will enable more comprehen-
sive BC risk assessment in genetics and oncology practice.
Methods
This was a cross-sectional study based on an international
survey.
We conducted an online survey (Bredart et al. 2018) in-
volving one reminder using the LimeSurvey application
(http://www.limesurvey.org) (LimeSurvey Project Team,
Carsten Schmitz 2015) during May to September 2016.
The survey targeted clinicians who were among the poten-
tial 7500 individuals who registered to use the BWA since
2007. In addition, BRIDGES investigators were asked to con-
tact members of their national genetics societies (NGS) to
invite them to complete the survey (if they had not already
responded through the BOADICEAwebsite). A total of 225,
170, 37 and 32 individuals were contacted from the British,
French, Dutch and Swedish NGS, respectively.
Survey development
The survey questions addressed the following: (1) practice in
genetic counselling and testing for cancer predisposition; (2)
importance attributed to BC familial, hormonal, reproductive
and lifestyle BC risk factors; (3) knowledge/usage frequency
of the Gail (Gail et al. 1989), Claus (Claus et al. 1991;
Parmigiani et al. 2007), Myriad (Shattuck-Eidens et al. 1997;
Frank et al. 2002), BRCAPRO (Parmigiani et al. 1998;
Mazzola et al. 2015), IBIS (International Breast Cancer
Study) (Tyrer et al. 2004; Quante et al. 2012; Brentnall et al.
2015; Cuzick et al. 2016) and BWA (Antoniou et al. 2004,
2008; Cunningham et al. 2012; MacInnis et al. 2013; Lee
et al. 2014, 2016) BC risk assessment tools, and Manchester
Scoring System (MSS) (Evans et al. 2004, 2005) and data entry
timing using these tools; and (4) socio-demographic and pro-
fessional background (Supplementary material A).
The questionnaire was developed in line with BRIDGES
program objectives, which specified an assessment of the ac-
ceptability of the BOADICEAmodel and the BWA in clinical
practice. As the next BWA update is expected to integrate
non-genetic and additional genetic BC risk factors, we
assessed the degree of importance attributed to familial, hor-
monal, reproductive and lifestyle risk factors to BC risk as-
sessment (Harvie et al. 2015). For each BC risk factor, five
response options from least to most important were provided
(see Table 4).
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We assessed BWA use with that of six other BC risk as-
sessment tools that could be used in family cancer clinics,
implementing the Gail (Gail et al. 1989), Claus (Claus et al.
1991; Parmigiani et al. 2007), Myriad (Shattuck-Eidens et al.
1997; Frank et al. 2002), BRCAPRO (Parmigiani et al. 1998;
Mazzola et al. 2015) or IBIS (Tyrer et al. 2004; Quante et al.
2012; Brentnall et al. 2015; Cuzick et al. 2016) models or
MSS (Evans et al. 2004, 2005).
These models focus primarily on family/personal cancer
history. Their distinctive features are briefly summarised
below and described in a table adapted from Kurian et al.
(2016) and Cintolo-Gonzalez et al. (2017) (Table 1). The
Gail model (or NCI Breast Cancer Risk Assessment Tool:
BCRAT) (Gail et al. 1989) and Claus model (Claus et al.
1991; Parmigiani et al. 2007) are used to compute BC risk
(only Gail incorporates both reproductive and familial
BC risk factors). The MSS (Evans et al. 2004, 2005)
and Myriad I or II models (Shattuck-Eidens et al. 1997;
Frank et al. 2002) are used to compute the probability
of carrying a deleterious BRCA1 and/or BRCA2 muta-
tion based on cancer family history. In addition to
familial/personal BC risk factors, the MSS also accounts
for the presence of a BRCA1 or BRCA2 mutation, breast
cancer pathology and cancers other than breast or ovar-
ian. The BRCAPRO (Parmigiani et al. 1998; Mazzola
et al. 2015), IBIS (Tyrer et al. 2004; Quante et al. 2012;
Brentnall et al. 2015; Cuzick et al. 2016) and
BOADICEA (Antoniou et al. 2004, 2008; Cunningham
et al. 2012; MacInnis et al. 2013; Lee et al. 2014, 2016)
models predict BRCA1 or BRCA2 mutation carrier prob-
ability and BC risk. In addition, BRCAPRO and
BOADICEA predict contralateral breast and ovarian
cancer risk (Cintolo-Gonzalez et al. 2017). BRCAPRO
incorporates family history, BRCA1 or BRCA2 mutation
status, molecular markers, mastectomy/oophorectomy
and ethnicity factors. IBIS incorporates not only family
history, BRCA1 or BRCA2 mutation status and breast
cancer pathology but also reproductive, hormone re-
placement therapy (HRT) and body mass index (BMI)
BC risk factors. The BOADICEA model allows for ex-
tensive family history; tumour pathology such as
oestrogen and progesterone receptors and HER2, CK5/
6 and CK14 status of BC in family member(s) to be
taken into account (Lee et al. 2014). BOADICEA also
includes the effects of truncating mutations in PALB2,
CHEK2 and ATM (Lee et al. 2016).
Table 1 Factors included in common breast cancer risk assessment tools
Output of breast cancer risk assessment tool Predicting breast cancer
risk
Predicting genetic carrier
status
Predicting breast cancer risk and carrier status
Factors Gail Claus Manchester Myriad BRCAPRO IBIS BOADICEA
Family cancer history Yes/1st d° Yes/1st and 2nd Yes/Extensive Yes/1st and 2nd Yes/Extensive Yes/1st and 2nd Yes/Extensive
Personal breast cancer (age at) Yes Yes Yes Yes Yes Yes Yes
BRCA1/2 mutation No No Yes No Yes Yes Yes
Common low-risk alleles No No No No No No No
Intermediate-high risk mutations
(CHEK2, PALB2, ATM, etc.)
No No No No No No Yes
Residual non-BRCA1/2 familial aggregation No No No No No Yes Yes
BRCA1/2 risk modification
by family history
No No No No No No Yes
Breast cancer pathology associations No No Yes No Yes Yes Yes
Mammography density No No No No No No No
Hormonal, lifestyle,
reproductive risk factors
Yes No No No No Yes No
Body mass index No No No No No Yes No
Breastfeeding No No No No No No No
Age at menarche Yes No No No No Yes No
Age at 1st birth Yes No No No No Yes No
Age at menopause No No No No No Yes No
Oral contraception No No No No No No No
Hormone replacement therapy No No No No No Yes No
Alcohol consumption No No No No No No No
Smoking No No No No No No No
Physical exercise No No No No No No No
Other cancers (non-breast/ovarian) No No Yes No Yes No Yes
Predicting second cancer risks
(contralateral, ovarian)
No No No No Yes No Yes
Italicized entries correspond to non-genetic risk factors
Adapted from Kurian et al. (2016); Cintolo-Gonzalez et al. (2017)
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For all seven BC risk assessment tools, we assessed knowl-
edge (‘I don’t know the model’), use frequency on a five-point
Likert scale ranging from never to always (see Table 3) and
convenience (i.e. the time required for data entry).
A preliminary version of the overall survey was designed
following survey method recommendations (Edwards et al.
2009; Cottrell et al. 2015). It was pilot-tested with clinical
geneticists, genetic counsellors, gynaecologists, psycho-on-
cologists, a radiotherapist and a methodologist (n = 21).
Data analysis
As shown in Fig. 1, 525 and 203 respondents’ data were
extracted from the BOADICEA website and NGS survey
sources respectively. The response rate obtained from the
BOADICEA website survey source could not be estimated
as the survey was sent to registered individuals who might
no longer use the tool, and tracking the tool use is not legally
permitted. Among respondents contacted through NGS, the
response rate was 43.7% (203 respondents out of 464 NGS
members, excluding those who responded through the
BOADICEAwebsite).
Based on psychometric analyses (Husson et al. 2011;
Jolliffe 2002), we developed indicators of genetic clinical ac-
tivity level (i.e. one scale comprising six survey items), and of
importance attributed to BC risk factors (i.e. five single items
addressing familial and personal cancer history, breast tumour
pathology, BMI and breastfeeding), and three multi-item
scales corresponding to hormonal BC risk factors (i.e. oral
contraception, HRT and exogenous hormone consumption),
reproductive BC risk factors (i.e. age at first menstrual period,
age at menopause and child bearing at younger age), and
lifestyle BC risk factors (i.e. alcohol consumption, smoking
and physical activity).
Knowledge and usage frequency were reported in percent-
ages. We computed the number of respondents by the number
of BC risk assessment tools used at least occasionally or reg-
ularly. Correlation coefficients were calculated between the
usage frequencies of the different BC risk assessment tools.
We compared the degree of importance attributed to each BC
risk factor by health profession (i.e. clinical geneticists, genet-
ic counsellors or nurses and oncology specialists) using a chi-
squared test.
Logistic multiple regression analyses (Tabachnick and
Fidell 2013) were performed on dichotomized variables ad-
dressing knowledge and usage frequency of six of the BC risk
assessment tools (excluding Myriad which received less than
100 responses) comparing ignorance of the tool or absent use
versus regular or more frequent use.
We explored clinicians’ background characteristics and the
degree of importance that they attributed to different BC risk
factors as potential explanatory variables, controlling for gen-
der. Age was significantly correlated to respondents’ clinical
seniority, so to maintain parsimony, it was not included as an
explanatory variable.
In further multivariate analyses, we tested the effect of data
entry time for each BC risk assessment tool, including only
respondents who use the respective tools. The logarithm of
data entry time was computed to allow a normal data
distribution.
Statistical analyses were performed with R software ver-
sion 3.3.1 (R Core Team 2016).
Results
Overall, 443 respondents completed at least 50% of the sur-
vey, comprising 316 (71.3%) and 127 (28.7%) via the
BOADICEA website and NGS survey sources respectively
(Fig. 1). Due to missing responses, especially in the last sec-
tions of the questionnaire, less data on socio-demographics
and professional characteristics are available (N = 394).
Survey sent through BWA
N=7500 email addresses
May to
September
2016
(one reminder)
Data extracted
N=525
Survey sent through
naonal CGS
N=464 email addresses*
Data extracted
N=203
Respondents to
at least 50%
survey items
N=316 (60.2%) N=127 (62.6%)
UK
N=225
FR
N=170
NL
N=37
SE
N=32
UK
RR=12%
FR
RR=38%
NL
RR=0%$
SE
RR=56%
Fig. 1 Respondents’ sample
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Sample characteristics
As shown in Table 2, a wide range of geographical regions/
countries were represented among respondents, including
Southern Europe (28%), Western Europe (21%), UK (20%),
North America (18%), Australia (8%) and other countries
(6%). Respondents also varied in terms of age and years of
clinical experience but were mainly female (77%); most had
received a specific training in cancer genetic counselling and
testing (70%) and had a clinical activity of 5 to 10 patients per
week (42%).
Breast cancer risk assessment tool knowledge
and usage frequency
The proportion of participants who did not know one of the
BC risk assessment tools included in the survey (excluding the
BWAwhich was reported as not known by two respondents)
ranged from 24 (5%) (BRCAPRO) to 61 (14%) (Myriad).
The BWA was used at least occasionally by 413 survey
participants (93%) (Table 3). The Gail, Claus, MSS, Myriad,
BRCAPRO and IBIS tools were used at least occasionally by
25, 27, 37, 13, 30 and 41% respondents, respectively.
Regarding the number of tools that were used, the
most common observation was the use of one tool at
least regularly, by 36% of respondents. The usage fre-
quency of the BWA and other tools was uncorrelated;
only the usage frequency of Gail was correlated to the
use other tools, i.e. Myriad (r = 0.51), Claus (r = 0.45),
BRCAPRO (r = 0.44) and IBIS (r = 0.41) (data not
shown).
Breast cancer risk assessment tool data completion
time
Over the different BC risk assessment tools, the mean (stan-
dard deviation) time in minutes to input clinical data ranged
from 3.6 (3.6) (MSS) to 15.6 (10.8) (BWA) (Supplementary
material B).
Perceived importance of breast cancer risk factors
To estimate BC risk, cancer family history was per-
ceived as most important by most respondents (72%).
Non-genetic BC risk factors were perceived as most
important by between 1.3% (breastfeeding, oral contra-
ception) and 5.4% (age at first menstrual period) of
respondents (Table 4).
Familial history of cancer was perceived as most im-
portant significantly more by geneticists than oncology
health professionals (p ≤ 0.01). More genetic counsellors/
nurses than other health professionals considered breast
tumour pathology as most important (p ≤ 0.01) (Tables 4
and 5).
Oncology health professionals attributed higher im-
portance to the following BC risk factors than genetics
health professionals: breastfeeding (p ≤ 0.05), alcohol
consumption (p ≤ 0.0001), oral contraception (p ≤ 0.01),
HRT (p ≤ 0.0001) and physical exercise (p ≤ 0.01).
Predictors of breast cancer risk assessment tool usage
frequency
The professional background characteristics were not as-
sociated with the frequency of use of BRCAPRO or the
BWA.
Genetic counsellors/nurses and oncology health pro-
fessionals used the following tools more frequently than
clinical geneticists: Gail (OR [CI] = 12.30 [3.17–47.9];
OR [CI] = 13.60 [2.82–65.2]) and IBIS (OR [CI] = 8.41
Table 2 Sample characteristics (N = 394)
Respondents N (%)
Age 20–39 198 (50)
40–49 82 (21)
> 50 114 (29)
Gender Female 305 (78)
Country Australia 30 (8)
North America (Canada, USA) 69 (18)
UK 77 (20)
Southern Europe (e.g. France,
Italy, Spain)
111 (28)
Western Europe (e.g. Belgium,
Germany, Netherlands, Sweden)
81 (21)
Others (e.g. Argentina, Estonia,
India, Israel, Taiwan)
25 (6)
Health profession Clinical geneticists 115 (29)
Genetic counsellors/nurses 209 (53)
Oncology specialists (e.g.
gynaecologists,
oncologists, surgeons, breast
specialists, etc.)
48 (12)
Others (e.g., genetic lab, (bio)
statisticians, etc.)
22 (6)
Seniority/clinical
experience
< 6 years 109 (28)
6–15 years 147 (38)
> 15 years 130 (34)
Training relevant to
genetics
Yes 274 (70)
Level of clinical
activitya
Low 176 (40)
Medium 185 (42)
High 82 (18)
aN = 443 as this question appeared in the survey beginning and so was
answered by more respondents; low = about 5 patients; medium = about
5–10 patients; high > 10 patients/week
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[3.39–20.8]; OR [CI] = 5.47 [1.79–16.6]). In addition,
genetic counsellors/nurses used the MSS more frequent-
ly than clinical geneticists (OR [CI] = 3.22, [1.64–6.27]).
Longer clinical experience was associated with a more
frequent use of the Gail (OR [CI] = 2.97 [1.01–8.79]),
Claus (OR [CI] = 3.06 [1.23–7.54]) and IBIS (OR
[CI] = 2.61 [1.12–6.10]) tools. The level of clinical ac-
tivity and specific cancer genetic counselling and testing
training was not associated with the use of any of these
tools.
To estimate BC risk, respondents who attributed less im-
portance to personal BC (OR [CI] = 0.49 [0.28–0.86]) and
more importance to breast tumour pathology (OR [CI] =
3.90 [1.90–7.97]) used the BWA more frequently; the reverse
was (unexpectedly) observed for the Gail (personal BC histo-
ry: OR [CI] = 2.66 [1.10–6.46]; breast tumour pathology: OR
[CI] = 0.21 [0.07–0.62]) and Claus (personal BC history: OR
[CI] = 2.56 [1.24–5.26]; breast tumour pathology: OR [CI] =
0.41 [0.18–0.92]) tools. The use of the BWA was
(unexpectedly) associated with the importance given to hor-
monal (exogenous) factors (OR [CI] = 1.77 [1.20–2.60]).
Considering reproductive BC factors as important was asso-
ciated with more frequent use of the Gail (OR [CI] = 3.06
[1.67–5.65]), Claus (OR [CI] = 1.88 [1.13–3.11]) and IBIS
(OR [CI] = 4.81 [2.86–8.14]) tools and less frequent use of
the MSS (OR [CI] = 0.57 [0.38–0.86]). IBIS was used less
frequently by individuals who considered breastfeeding as
important (OR [CI] = 0.53 [0.33–0.86]).
Among non-genetic BC risk factors, the importance attrib-
uted to lifestyle and BMI risk factors to estimate BC risk was
not associated with the use of any of these tools.
Discussion
Respondents to this survey were mostly BWA users
(93%), and few were unaware of other BC risk assess-
ment tools commonly used in cancer genetics clinics.
Thus, results presented here describe factors that
potentially influence the respondents’ choice of using
the BWA or another tool.
Uptake of a BC risk assessment tool may depend on
its perceived validity, which is related to the type and
number of BC risk factors incorporated within the un-
derlying statistical model and any accompanying valida-
tion studies. So, in line with the characteristics of the
BC risk assessment tools (described in Table 1), respon-
dents who attributed more importance to breast tumour
pathology risk factors used the BWA more frequently
and used the Gail and Claus tools less frequently.
Similarly, those who attributed more importance to re-
productive factors used the Gail and IBIS tools more
frequently. However, the relationship between some
BC risk factors considered important by our respondents
and the more frequent use of some tools was unexpect-
ed, given that some tools do not include the BC risk
factors considered important by their users (perhaps sug-
gesting lack of understanding of the underlying risk
model). For example, we found that the use of the
BWA was related to the importance attributed to exog-
enous hormonal BC factors even though this model
does not take these BC risk factors into account. In this
study, most respondents regularly used only one tool. It
is possible that one tool is selected to optimally respond
to one’s major clinical needs. For example, the BWA
may be used, in spite of not currently accounting for
hormonal factors, because it considers a number of fa-
milial and genetic factors.
Uptake of a BC risk assessment tool may also depend on
the health professional’s patient population and role (i.e. to
guide referral to family history clinics, to assess BC risk or
the probability of harbouring a deleterious mutation, to make
oncology treatment decisions, to advise on cancer risk man-
agement). Respondents’ professional background appeared
related to the importance attributed to familial or hormonal,
reproductive and lifestyle factors. This may explain the dis-
tinct uptake of some BC risk assessment tools according to the
type of respondents’ profession. Indeed, oncology specialists
Table 3 Breast cancer risk assessment tool knowledge and use frequency among respondents (N = 443)
To estimate breast cancer risk, how often do you use the following gene mutation or cancer risk prediction models? N (%)
Tool (number of users) Don’t know
the model
Never Occasionally Regularly Always
Gail (N = 109) 46 (10) 288 (65) 52 (12) 40 (9) 17 (4)
Claus (N = 119) 40 (9) 284 (64) 54 (12) 37 (8) 28 (4)
Manchester (N = 162) 54 (12) 227 (51) 46 (10) 46 (10) 70 (16)
Myriad (N = 56) 61 (14) 326 (74) 36 (8) 12 (3) 8 (2)
BRCAPRO (N = 132) 24 (5) 287 (65) 61 (14) 42 (9) 29 (7)
IBIS (N = 180) 34 (8) 229 (52) 67 (15) 76 (17) 37 (8)
BOADICEA (N = 413) 2 (1) 28 (6) 105 (24) 169 (38) 139 (31)
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Table 4 Importance of breast cancer risk factors as perceived by clinical geneticists (N = 115), genetic counsellors or nurses (N = 209) and oncology
specialists (N = 48)
For you, how important are the following factors to estimate breast cancer risk?
Perceived degree of importance—N (%)
1 (least) 2 3 4 5 (most)
Familial cancer history**
Clinical geneticists 1 (0.1) 0 (0.0) 0 (0.0) 22 (19.1) 92 (80.0)
Genetic counsellors/nurses 0 (0.0) 0 (0.0) 5 (2.4) 52 (24.9) 152 (72.7)
Oncology specialists 1 (2.1) 1 (2.1) 1 (2.1) 20 (41.7) 25 (52.1)
Total 2 (0.5) 1 (0.3) 6 (1.6) 94 (25.3) 269 (72.3)
Personal cancer history
Clinical geneticists 1 (0.1) 3 (2.6) 8 (7.0) 37 (32.2) 66 (57.4)
Genetic counsellors/nurses 0 (0.0) 1 (0.5) 12 (5.7) 83 (39.7) 113 (54.1)
Oncology specialists 1 (2.1) 1 (2.1) 8 (16.7) 18 (37.5) 20 (41.7)
Total 2 (0.5) 5 (1.3) 28 (7.5) 138 (37.1) 199 (53.5)
Breast tumour pathology**
Clinical geneticists 3 (2.6) 18 (15.7) 32 (27.8) 44 (38.3) 18 (19.8)
Genetic counsellors/nurses 0 (0.0) 10 (4.8) 54 (25.8) 82 (39.2) 63 (30.1)
Oncology specialists 2 (4.2) 4 (8.3) 15 (31.2) 17 (35.4) 10 (20.8)
Total 5 (1.3) 32 (8.6) 101 (27.2) 143 (38.4) 91 (24.5)
Age at first menstrual period
Clinical geneticists 27 (23.5) 42 (36.5) 34 (29.6) 9 (7.8) 3 (2.6)
Genetic counsellors/nurses 43 (20.6) 62 (29.7) 62 (29.7) 28 (13.4) 14 (6.7)
Oncology specialists 10 (20.8) 13 (27.1) 15 (31.2) 7 (14.6) 3 (6.2)
Total 80 (21.5) 117 (31.5) 111 (29.8) 44 (11.8) 20 (5.4)
Age at menopause
Clinical geneticists 24 (20.9) 40 (34.8) 37 (32.2) 12 (10.4) 2 (1.7)
Genetic counsellors/nurses 33 (15.8) 59 (28.2) 66 (36.1) 38 (10.2) 13 (6.2)
Oncology specialists 4 (8.3) 14 (29.2) 21 (43.8) 6 (12.5) 3 (6.2)
Total 61 (16.4) 113 (30.4) 124 (33.3) 56 (15.1) 18 (4.8)
Body mass index
Clinical geneticists 21 (18.3) 42 (36.5) 32 (27.8) 15 (13.0) 5 (4.3)
Genetic counsellors/nurses 34 (16.3) 71 (34.0) 61 (29.2) 35 (16.7) 8 (3.8)
Oncology specialists 2 (4.2) 11 (22.9) 17 (35.4) 13 (27.1) 5 (10.4)
Total 57 (15.3) 124 (33.3) 110 (29.6) 63 (16.9) 18 (4.8)
Child bearing at younger age
Clinical geneticists 23 (20.0) 40 (34.8) 38 (33.0) 13 (11.3) 1 (0.9)
Genetic counsellors/nurses 29 (13.9) 72 (34.4) 66 (31.6) 30 (14.4) 12 (5.7)
Oncology specialists 6 (12.5) 14 (29.2) 13 (27.1) 11 (22.9) 4 (8.3)
Total 58 (15.6) 126 (33.9) 117 (31.5) 54 (14.5) 17 (4.6)
Breastfeeding*
Clinical geneticists 21 (18.3) 37 (32.2) 44 (38.3) 12 (10.4) 1 (0.9)
Genetic counsellors/nurses 29 (13.9) 83 (39.7) 63 (30.1) 33 (15.8) 1 (0.5)
Oncology specialists 5 (10.4) 16 (33.3) 14 (29.2) 10 (20.8) 3 (6.2)
Total 55 (14.8) 136 (36.6) 121 (32.5) 55 (14.8) 5 (1.3)
Alcohol consumption****
Clinical geneticists 34 (29.6) 42 (36.5) 28 (24.3) 7 (6.1) 4 (3.5)
Genetic counsellors/nurses 39 (18.7) 89 (42.6) 56 (26.8) 23 (11.0) 2 (1.0)
Oncology specialists 4 (8.3) 13 (27.1) 14 (29.2) 15 (31.2) 2 (4.2)
Total 77 (20.7) 144 (38.7) 98 (26.3) 45 (12.1) 8 (2.2)
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attributed more importance to hormonal and lifestyle factors
and also used the Gail and IBIS tools more frequently than
clinical geneticists. However, genetic counsellors and nurses
also used these tools more frequently as well as the MSS,
which may be related to role sharing between medical and
non-medical genetics clinicians. BWA use was not related to
the type of health profession or the use of other tools, suggest-
ing that this tool may respond to various clinical needs.
In contrast, the Gail tool was moderately associated with
the use of other tools such as Claus, Myriad, BRCAPRO and
IBIS. In fact, our respondents were mostly genetics clinicians,
and validation studies suggest that Gail is less appropriate to
assess BC risk in hereditary high-risk populations [Evans and
Howell 2007]. Moreover, Gail does not predict mutation car-
rier status, so this tool seems to require a complementary as-
sessment tool for professionals in this survey.
Uptake of BC risk assessment tools may be related to us-
ability and ease of data entry (e.g. depending on the amount of
information) and accessibility (i.e. availability on theWeb and
ease with which statistical outputs can be understood and
communicated to patients). In this study, only the uptake of
Claus and theMSSwas related to the usability of the tool (data
presented in supplementary material C). In cancer genetics
clinics, these tools may be used systematically for all patients
to appraise the need for genetic testing and so they must be
easy to use. In contrast, it is possible that tools with lower
usability (that require more time to enter data) such as the
BWA may be acceptable in specific situations, e.g. to refine
a BC risk assessment or estimate the risk of contralateral BC
and other cancers.
The importance given to lifestyle and BMI BC risk factors
was not associated with the use of any tool. This was expected
as the BC risks associated with these risk factors are not as
high as those associated with genetic risks (Amir et al. 2010;
Kurian et al. 2016). Moreover, IBIS was the only tool that
takes BMI into account in risk calculations. The presence of
a substantial family history of BC and the likelihood of carry-
ing a deleterious mutation are important when predicting the
incidence of BC, and thus are the focus of genetics clinicians.
However, BMI (Quante et al. 2015; Lecarpentier et al. 2015)
and reproductive and hormonal BC risk factors (Lecarpentier
et al. 2015) seem to modify the BC risk associated with high-
risk genetic variants. Moreover, the influence of lifestyle on
BC risk has also been suggested among women at increased
risk or with a BRCA1/2 gene mutation (Easton et al. 2015).
Lifestyle factors may be targeted for change by health inter-
ventions to reduce BC risk (Meads et al. 2012). Studies have
shown that discussion of these factors with counselees is
Table 4 (continued)
For you, how important are the following factors to estimate breast cancer risk?
Perceived degree of importance—N (%)
1 (least) 2 3 4 5 (most)
Smoking
Clinical geneticists 31 (27.0) 38 (33.0) 29 (25.2) 15 (13.0) 2 (1.7)
Genetic counsellors/nurses 42 (20.1) 70 (33.5) 58 (27.8) 31 (14.8) 8 (3.8)
Oncology specialists 15 (31.2) 14 (29.2) 9 (18.8) 6 (12.5) 4 (8.3)
Total 88 (23.7) 122 (32.8) 96 (25.8) 52 (14.0) 14 (3.8)
Oral contraception**
Clinical geneticists 21 (18.3) 40 (34.8) 42 (36.5) 12 (10.4) 0 (0.0)
Genetic counsellors/nurses 22 (10.5) 57 (27.3) 90 (43.1) 38 (18.2) 2 (1.0)
Oncology specialists 9 (18.8) 18 (37.5) 9 (18.8) 9 (18.8) 3 (6.2)
Total 52 (14.0) 115 (30.9) 141 (37.9) 59 (15.9) 5 (1.3)
Hormone replacement therapy****
Clinical geneticists 13 (11.3) 27 (23.5) 48 (41.7) 23 (20.0) 4 (3.5)
Genetic counsellors/nurses 6 (2.9) 34 (16.3) 93 (44.5) 66 (31.6) 10 (4.8)
Specialists 1 (2.1) 11 (22.9) 15 (31.2) 11 (22.9) 10 (20.8)
Total 20 (5.4) 72 (19.4) 156 (41.9) 100 (26.9) 10 (2.7)
Physical exercise**
Clinical geneticists 24 (20.9) 36 (31.3) 41 (35.7) 7 (6.1) 7 (6.1)
Genetic counsellors/nurses 32 (15.3) 76 (36.4) 68 (32.5) 32 (15.3) 1 (0.5)
Oncology specialists 4 (8.3) 14 (29.2) 15 (31.2) 13 (27.1) 2 (4.2)
Total 60 (16.1) 126 (33.9) 124 (33.3) 52 (14.0) 10 (2.7)
Comparison of type of clinicians by the degree of importance attributed to each BC factors: *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001
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variable across health professional specialties (Julian-Reynier
et al. 2015) and may be infrequent in clinical genetics practice
(Albada et al. 2014). As the next version of the BWA will
incorporate these BC risk factors, this updated tool may facil-
itate more comprehensive BC risk counselling.
Our study has several limitations:
1. This survey was conducted via the BOADICEA website
and European NGS, and so the respondent sample mainly
comprised BWA users and European genetics clinicians.
Thus, our findings may not be generalised to other, more
diverse clinician populations in other geographic areas. In
Canada, for example, general practitioners, specialists and
genetic counsellors most frequently used the BRCAPRO
and Gail tools, whereas the BWAwas less frequently used
(by 13% compared to 25 and 18% for the BRCAPRO and
Gail, respectively) (Amara et al. 2015).
2. Some BC risk assessment tools investigated were used by
a limited number of respondents, and so we may have
lacked power to provide reliable estimates of the BC risk
factors related to their use. In addition, the overall high
usage frequency of BWA in this sample and thus the lack
of variation in this tool usage frequency may have also
hampered the detection of some relationships. For
example, although some experience is needed for
proper use of the BWA, more frequent use of some
of the investigated tools (but not BWA) was related
to increased clinicians’ seniority.
3. The survey design allows us to comment on the associa-
tions, but we cannot ascertain the directionality of the
relationships, nor their specificity over time, along stages
of the BC genetic counselling process.
Conclusion
Our study provides novel insights into the acceptability of the
BWA by analysis of BC risk factors incorporated in this tool
and other common BC risk assessment tools. These results
suggest that while the BWA does fulfil various clinicians’
needs, it does not incorporate some BC risk factors considered
Table 5 Factors associated to breast cancer risk assessment tool use (N = 370)—odds ratios [confidence interval]
Gail Claus Manchester BRCAPRO IBIS BOADICEA
Gender (male) 5.15 [2.14–13.6]** 1.26 [0.57–2.80] 0.83 [0.42–1.61] 2.59
[1.26–5.33]**
1.43 [0.68–2.99] 0.80 [0.43–1.48]
Medical profession
(Genetic counsellors
vs Clinical geneticists)
12.30
[3.17–47.9]***
2.20 [0.97–5.03] 3.22
[1.64–6.27]***
1.22 [0.56–2.63] 8.41
[3.39–20.8]***
0.64 [0.34–1.20]
Medical profession
(oncology specialists
vs clinical geneticists)
13.60
[2.82–65.2]***
1.06 [0.31–3.65] 0.90 [0.32–2.43] 0.30 [0.07–1.21] 5.47 [1.79–16.6]** 0.48 [0.20–1.15]
Level genetic clinical activity 1.55 [0.94–2.54] 1.26 [0.86–1.84] 0.90 [0.66–1.24] 1.34 [0.93–1.93] 1.36 [0.95–1.97] 0.99 [0.72–1.35]
Experience (6–15 vs < 6 years) 1.13 [0.41–3.10] 1.95 [0.84–4.50] 0.94 [0.52–1.73] 1.48 [0.67–3.26] 1.19 [0.58–2.43] 1.09 [0.58–2.08]
Experience (> − 15 vs
< 6 years)
2.97 [1.01–8.79]* 3.06
[1.23–7.54]*
1.48 [0.74–2.95] 1.51 [0.62–3.61] 2.61 [1.12–6.10]* 0.82 [0.41–1.65]
Specific genetic
training (Yes)
1.67 [0.60–4.52] 1.23 [0.57–2.71] 1.48 [0.82–2.66] 1.21 [0.56–2.59] 1.77 [0.84–3.72] 0.66 [0.36–1.20]
Family cancer history
(more important)
0.59 [0.25–1.40] 1.09 [0.51–2.34] 1.11 [0.62–1.98] 0.71 [0.35–1.46] 1.13 [0.58–2.20] 1.52 [0.87–2.66]
Personal cancer history
(more important)
2.66 [1.10–6.46]* 2.56
[1.24–5.26]*
0.80 [0.45–1.43] 1.26 [0.61–2.57] 0.80 [0.41–1.58] 0.49 [0.28–0.86]*
Breast tumour pathology
(more important)
0.21 [0.07–0.62]** 0.41
[0.18–0.92]*
1.58 [0.86–2.93] 1.08 [0.50–2.36] 0.63 [0.30–1.35] 3.90
[1.90–7.97]***
Body mass index
(more important)
0.10 [0.56–1.75] 0.67 [0.41–1.10] 1.14 [0.77–1.68] 0.87 [0.53–1.40] 1.15 [0.73–1.82] 0.91 [0.61–1.36]
Breastfeeding (more important) 1.28 [0.72–2.28] 1.15 [0.70–1.90] 1.06 [0.72–1.57] 1.02 [0.62–1.66] 0.53 [0.33–0.86]** 0.70 [0.47–1.06]
Reproductive risk factor
(more important)a
3.06 [1.67–5.65]*** 1.88
[1.13–3.11]*
0.57 [0.38–0.86]** 1.63 [0.99–2.69] 4.81
[2.86–8.14]***
0.77 [0.51–1.16]
Hormonal risk factor
(more important)a
1.18 [0.66–2.14] 0.99 [0.62–1.58] 1.20 [0.84–1.71] 1.16 [0.73–1.87] 0.99 [0.64–1.54] 1.77 [1.20–2.60]**
Lifestyle risk factor
(more important)a
0.76 [0.42–1.39] 1.17 [0.70–1.94] 1.31 [0.88–1.95] 1.05 [0.63–1.74] 0.63 [0.38–1.02] 1.14 [0.75–1.73]
Nagelkerke pseudo-R2 0.40 0.15 0.15 0.12 0.41 0.14
Never/occasional or do not know= 0 versus at least regular use = 1
a Reproductive, hormonal, lifestyle factors include (1) age at first menstrual period, age at menopause, child bearing at younger age; (2) oral contracep-
tion, hormone replacement therapy; (3) alcohol consumption, smoking, physical activity, respectively
*p < 0.05; **p < 0.01; ***p < 0.001
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important by its users. The results of our analyses will help to
identify perceived deficiencies in the BWA and guide further
software development (including integration of additional ge-
netic and non-genetic BC risk factors), so that the next version
of the BWA will facilitate more comprehensive BC risk as-
sessment in genetics and oncology practice.
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